Cargando…

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It

Classic Hodgkin lymphoma (cHL) is characterized by a few tumor cells surrounded by a protective, immunosuppressive tumor microenvironment composed of normal cells that are an active part of the disease. Hodgkin and Reed–Sternberg (HRS) cells evade the immune system through a variety of different mec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aldinucci, Donatella, Borghese, Cinzia, Casagrande, Naike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566335/ https://www.ncbi.nlm.nih.gov/pubmed/31096713 http://dx.doi.org/10.3390/ijms20102416

Ejemplares similares

Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma
por: Casagrande, Naike, et al.
Publicado: (2022)

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

The CCL5/CCR5 Axis in Cancer Progression
por: Aldinucci, Donatella, et al.
Publicado: (2020)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
por: Borghese, Cinzia, et al.
Publicado: (2020)

Analogs of a Natural Peptaibol Exert Anticancer Activity in Both Cisplatin- and Doxorubicin-Resistant Cells and in Multicellular Tumor Spheroids
por: Casagrande, Naike, et al.
Publicado: (2021)

Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
por: Aldinucci, Donatella, et al.
Publicado: (2018)

In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel
por: Casagrande, Naike, et al.
Publicado: (2021)

Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
por: Georgoulis, Vasileios, et al.
Publicado: (2023)

Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist
por: Carreau, Nicole A., et al.
Publicado: (2019)

Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
por: Martynchyk, Arina, et al.
Publicado: (2023)

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells
por: Borghese, Cinzia, et al.
Publicado: (2017)

Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Comment on “Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury” Cancers 2019, 11, 1687
por: Aldinucci, Donatella, et al.
Publicado: (2020)

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2022)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
por: Visser, Lydia
Publicado: (2018)

Inflammatory microenvironment in classical Hodgkin’s lymphoma with special stress on mast cells
por: Ribatti, Domenico, et al.
Publicado: (2022)

Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives
por: Altaf, Muhammad, et al.
Publicado: (2019)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
por: Romano, Alessandra, et al.
Publicado: (2016)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

Hodgkin Lymphoma: A Special Microenvironment
por: Opinto, Giuseppina, et al.
Publicado: (2021)

Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma
por: Chiu, Jodi, et al.
Publicado: (2018)

Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment
por: Post, Ginell R., et al.
Publicado: (2019)

The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
por: Ferrarini, Isacco, et al.
Publicado: (2020)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status
por: Altaf, Muhammad, et al.
Publicado: (2016)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
por: Camus, Vincent, et al.
Publicado: (2021)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma
por: Bertuzzi, Clara, et al.
Publicado: (2021)

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
por: Karihtala, Kristiina, et al.
Publicado: (2022)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_37mh16fuucege631tfkfb08gp2